COMIRNATY® JN.1 COVID-19 vaccine

Active ingredient: bretovameran

Consumer Medicine Information

This leaflet provides important information about using COMIRNATY JN.1. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about receiving COMIRNATY JN.1.

Where to find information in this leaflet:

- 1. Why am I being given COMIRNATY JN.1?
- 2. What should I know before I am given COMIRNATY JN.1?
- 3. What if I am taking other medicines?
- 4. How will I be given COMIRNATY JN.1?
- 5. What should I know while being given COMIRNATY JN.1?
- 6. Are there any side effects?
- 7. Product details

1. Why am I being given COMIRNATY JN.1?

COMIRNATY JN.1 contains the active ingredient bretovameran.

COMIRNATY JN.1 is an mRNA (messenger ribonucleic acid) vaccine.

COMIRNATY JN.1 is a vaccine given to prevent COVID-19 disease caused by SARS-CoV-2 virus in adults, infants and children from 6 months of age and older.

COMIRNATY JN.1 works by triggering your immune system to produce antibodies and blood cells that work against the virus, to protect against COVID-19 disease.